|
Status |
Public on Dec 31, 2014 |
Title |
UB_PXD101_01102009_07PB8219 |
Sample type |
RNA |
|
|
Source name |
mononuclear cells from peripheral blood
|
Organism |
Homo sapiens |
Characteristics |
age (years): 73 gender: female karyotype: t(11q23) group: CRorPR [responder (complete remission or partial remission)]
|
Treatment protocol |
Samples are from untreated patients (de novo AML)
|
Growth protocol |
not applicable
|
Extracted molecule |
total RNA |
Extraction protocol |
The total RNA was purified with a TRIzol-based protocol.
|
Label |
Biotin
|
Label protocol |
For each sample preparation, total RNA was converted into double-stranded cDNA by reverse transcription using the 3' IVT Express Kit from Affymetrix according to the manufacturer's recommendations.
|
|
|
Hybridization protocol |
Hybridization, washing, and staining protocols, respectively, were performed on Affymetrix GeneChip instruments (Hybridization Oven 640, Fluidics Station FS450) as recommended by the manufacturer.
|
Scan protocol |
Scanning was performed on Affymetrix GeneChip Scanner GCS3000 instruments as recommended by the manufacturer using default settings. The software used was GCOS 1.2 or higher.
|
Description |
006
|
Data processing |
The data were analyzed with BRB ArrayTools using RMA. Intensity values were log2 transformed
|
|
|
Submission date |
Jul 14, 2012 |
Last update date |
Dec 31, 2014 |
Contact name |
Lars Bullinger |
E-mail(s) |
lars.bullinger@charite.de
|
Phone |
+49-30-450-553111
|
Organization name |
Charité
|
Department |
Hematology, Oncology and Tumorimmunology
|
Street address |
Augustenburger Platz 1
|
City |
Berlin |
ZIP/Postal code |
13353 |
Country |
Germany |
|
|
Platform ID |
GPL570 |
Series (1) |
GSE39363 |
A Phase I/II Clinical Trial of PXD101 in Combination with Idarubicin in Patients with AML Not Suitable for Standard Intensive Therapy |
|